CD8A and neoplasm: In this study, by using a computational biology tool (silico approach), we developed AYA22T-R2-13, a CTLA4/NKG2A dual receptor aptamer that blocks the inhibitory CTLA4/NKG2A receptors unleashing both T and NK cells and promotes NK and CD8+ T cell effector functions of tumor cell lysis.